1 / 6

Overcoming barriers to innovation and ensuring access

Global Health Conference, Brussels, June 10-11, 2010. Overcoming barriers to innovation and ensuring access. Session C - Innovation and Access François Bompart, MD Sanofi Aventis - EFPIA. Access to healthcare (1). High percentage of global populations lacks adequate access to healthcare

bert-montoya
Download Presentation

Overcoming barriers to innovation and ensuring access

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Health Conference,Brussels, June 10-11, 2010 Overcoming barriers to innovation and ensuring access Session C - Innovation and Access François Bompart, MD Sanofi Aventis - EFPIA

  2. Access to healthcare (1) • High percentage of global populations lacks adequate access to healthcare • Does not exist • Too expensive • Too remote • Too difficult to deliver with existing infrastructure • Substandard • Healthcare deficiencies do not exist in isolation • Basic infrastructure (water, roads) • Insufficient Government budgets • Underdeveloped Healthcare financing systems • Lack of technical/scientific capacity

  3. Access to healthcare (2) • « Access to healthcare » broader issue than « Access to medicines » • Political will to invest in heathcare • Human resources & infrastructures • Insurance systems, public and private • Availability of prevention interventions • Sanitation, access to safe water and food, health information... • Access to medicines and other commodities • « Access to medicines » broader issue than « Price of medicines » • Drugs adapted to patients’ and health professionals’ needs • Availability of diagnostic methods • Information of healthcare providers, communities and patients • Efficiency of distribution systems • Drugs only go to places where someone orders them • Price of medicines and other commodities

  4. Innovation • Investments in innovation conditionned by science and market potential 1. Scientific lead + Potential market • Program included in « mainstream » pharmaceutical R&D 2. NO Scientific lead yet, but potential market • Research performed: academic and pharmaceutical 3. Scientific lead + NO Potential market • New economic model needed to include program in pharmaceutical R&D (Public-Private partnerships, incentive programs, etc.) • In pharmaceuticals, major innovations take >> 10 years to reach patients • Do not underestimate « small » innovations (e.g. antimalarial fixed-dose combinations, pediatric formulations, etc.)

  5. Poverty and lack of access to healthform a vicious circle • What will transform the vicious circle? • Economic growth • Domestic advocacy for better healthcare • Innovative approaches to financing • Improved access to healthcare • Research & Development for neglected diseases and patients • Focused and sustainable actions on specific health threats and horizontal programmes • Collective action through partnerships which bridge the developed and developing world

  6. What can the EU do ? • Promote idea of equity in access to health worldwide • Solidarity chain • Foster investment in healthcare by • Supporting the enabling conditions in developing countries • Seed funding for scientific infrastructure • Encourage development of partnerships • Promote efficient regulatory approaches • Help developing countries effectively control their own environment (e.g. quality of medicines) • Provide « even field » for innovators and investors • Develop incentives for innovation in neglected diseases and neglected patients • Including “small” innovations with quick impact • Chronic diseases as well as transmissible diseases

More Related